Pretreatment of RAW 264.7 macrophage cells with GHK-Cu has been shown to significantly decrease ROS levels induced by lipopolysaccharide (LPS), increase levels of SOD activities and total GSH, and decrease levels of TNF- and IL-6 production through the suppression of NF-B p65 and p38 MAPK signaling [22]
Explore more in our wellness center services .
BPC-157 and TB-500 are combined into one formulation, allowing researchers to work with a stable, pre-blended research material rather than handling individual components separately
has received research grants from Acceleron, Actelion, Bayer, Isarna, MSD, EMD Pharmaceuticals (Merck, Darmstadt), Novocure, Piqur and Roche and honoraria for lectures or advisory board participation or consulting from BMS, Celldex, Immunocellular Therapeutics, Isarna, Magforce, MSD, EMD Pharmaceuticals (Merck, Darmstadt), Northwest Biotherapeutics, Novocure, Pfizer, Roche, Teva and Tocagen
Flexible Research Integration